F-star is the only company able to rapidly create bispecific antibodies with properties virtually identical to a typical antibody. This is achieved by introducing a second binding site in the constant (Fc) region of an antibody. This offers unprecedented ease in the discovery, development, and manufacturing of bispecific antibody products. F-star is focused on developing treatments to improve the cancer therapy.
Classic monoclonal antibodies have two key regions:
- The variable (Fab) region that binds to a specific target protein
- The constant (Fc) region responsible for attracting the immune system
Bispecific antibodies are capable of binding two different targets concurrently. The approach offers many advantages over traditional antibody technologies such as:
- Targeting therapeutics to tissues or specific disease processes
- Mobilising multiple arms of the immune system in one drug
- Crosslinking cell-surface receptors to invoke novel biology with powerful therapeutic potential
F-star’s technology leverages decades of experience with traditional antibody technology, while overcoming all the commonly observed limitations in the development and manufacture of bispecific products. Our technology offers competitive therapeutic, development, manufacturing and commercial advantages over other available bispecific technologies. F-star’s Modular Antibody Technology™ enables the rapid creation of large panels of bispecific antibodies. Our drugs are able to offer meaningful synergistic benefits to patients not achievable by co-administration of individual drugs. This powerful technology, combined with F-star’s biology expertise, allows for the most efficient identification of those combinations of target specificities which will have the greatest potential for therapeutic benefit.
The rapid progress of F-star’s first clinical programme, FS102, demonstrates the capabilities of our platform. In less than 18 months, FS102 advanced from drug candidate, through scale-up, GMP manufacturing, and toxicology studies to a successful IND filing. FS102 is in Phase 1 clinical trials as part of our partnership with Bristol-Myers Squibb.